FlashCloud Intelligence Launches Social Intent, a Buying Intent Signal Data for B2B Sellers to Identify Interested Prospects on Social Media
San Francisco, California–(Newsfile Corp. – March 3, 2023) – FlashCloud Intelligence, a leading provider of…
Month: March 2023
Che Capital Asset Management Completes Acquisition of 62 Acres in Seguin, Texas, to Develop a Mixed-Use Retail and Multifamily Development
Chicago-based real estate investment firm Che Capital Asset Management announced their successful acquisition of a…
Future Blockchain Summit Teams up to Host First Bored Ape Yacht Club Party Outside the States
Dubai, United Arab Emirates–(Newsfile Corp. – March 3, 2023) – Future Blockchain Summit and local…
First Responder Announces Non-Brokered Private Placement
Vancouver, British Columbia–(Newsfile Corp. – March 3, 2023) – First Responder Technologies Inc. (CSE: WPN) (OTC…
Infinity Stone Refines Graphite to 99.73% Purity, Plans Spin Out of Rockstone Graphite Project
Highlights Infinity Stone successfully refines graphite samples from its Rockstone Graphite Project to 99.73% Cg…
DelphX Announces Closing of $660,200 Non-Brokered Unit Financing
Toronto, Ontario–(Newsfile Corp. – March 3, 2023) – DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB:…
Doubleview Provides Update on HAT Project 2021 and 2022 Drill Data
Vancouver, BC, Mar 3, 2023 – (ACN Newswire) – Doubleview Gold Corp. (TSXV: DBG) (OTCQB:…
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing…
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) — Ractigen Therapeutics announced today that the U.S….
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”),…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVIâ„¢ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule…
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase…
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no…
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
— Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line…
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),…
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in…
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., March 03, 2023 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global…
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”),…